Eris Lifesciences Q4 profit jumps 173% YoY in FY26

What changed in the March quarter

Eris Lifesciences reported a stronger March-quarter performance, supported by steady operating growth and a large deferred tax gain. For the quarter ended March, operating revenue rose 7% year-on-year to INR 757 crore. EBITDA increased 8% YoY to INR 274 crore, reflecting a relatively stable operating performance despite launch-related costs. Net profit nearly doubled to INR 279 crore in Q4, making it the key headline number in the results. The company attributed the sharp rise in profit to a deferred tax gain of INR 132.2 crore.

The quarter also included signs of margin pressure, which the company linked to pre-semaglutide launch expenses. That context is important because the company is simultaneously scaling its insulin franchise and entering the GLP-1 category through semaglutide. Management commentary indicated that near-term costs were tied to setting up the launch, while it expects margin benefits later as manufacturing gets internalised.

Q4 FY26 numbers at a glance

The Q4 update showed a mix of operating progress and one-off factors influencing bottom-line growth. Revenue and EBITDA grew at a mid-to-high single-digit pace, broadly matching the company’s recent operating trajectory. But profit growth was significantly higher due to the tax gain. That separation between operating trend and reported profit is likely to be a key point for investors tracking sustainable earnings.

Eris also reported a moderation in EBITDA margins in the quarter due to semaglutide launch-related expenses. At the same time, its broader model has historically supported strong profitability. The company has cited EBITDA margins of 35% to 36% and cash conversion rates of 75% to 80%.

Full-year FY26: revenue up 8%, profit up 73%

For the full financial year FY26, Eris reported revenue from operations of INR 3,129 crore, up 8% YoY. Net profit rose 73% YoY to INR 648 crore. Management positioned the year as one where domestic branded formulations remained a key driver, even as execution challenges in insulin supply impacted sales.

Within FY26, Eris said its domestic formulation business clocked INR 2,778 crore. The company attributed this to a strong uptick in insulin sales, claiming insulin growth outpaced the market by 5x. The company has also been building new growth levers through GLP-1, dermatology, and injectable franchises.

Insulin supply constraints and the Bhopal facility

Eris disclosed a hit to insulin sales due to supply-related issues. It booked a loss of INR 50 crore in insulin sales on account of supply constraints, which it linked to delays in commissioning its manufacturing facility in Bhopal. The facility is a key part of Eris’ plan to bring insulin manufacturing and formulation capabilities in-house.

In the human insulin segment, Eris competes with players including Lupin and Wockhardt. The company currently sources insulin supply from Biocon and MJ Biopharm, while it works toward internalising formulation manufacturing by year-end. It has also indicated that the near-term contribution window may be limited, stating it would “likely see four to five months of revenue contribution,” with the full-year impact expected in FY27.

Semaglutide launch: Sundae’s early traction

Eris said its semaglutide generic brand Sundae has started strongly in India, using a phased approach across vials and pens. The company stated the brand ranked No. 1 by volume among injectables in its first month of launch, as of April. Separately, the supplied context also notes that Sundae quickly captured 22% Rx share.

Amit Bakshi, Chairman and Managing Director, said the early performance validates Eris’ strategy of leveraging its insulin platform to secure a position in the GLP segment. The company has framed GLP-1 as a major category opportunity alongside its existing diabetes-focused franchise.

Natco partnership and the focus on margin improvement

Eris shares rose 2.17% to INR 1,380.65 after the company announced a strategic partnership with Natco Pharma for the commercialisation of semaglutide in India. Management has guided that for FY27, EBITDA margins are projected to stay around 37%, with further improvement expected in the second half.

A key operational lever discussed is the move toward in-house development of semaglutide pens, which management expects to contribute to margin gains under the co-marketing partnership. The article context also highlights that in-house semaglutide pen production is expected to support margins in FY27.

Biologics buildout: Levim Lifetech and Swiss Parenterals

Eris has also entered drug substance manufacturing via its investment in Levim Lifetech, which is developing recombinant products such as semaglutide. In 2024, Eris acquired a 30% stake in Levim for INR 54 crore, valuing the company at INR 180 crore. This investment fits into Eris’ broader push to strengthen its biotechnology and biologics portfolio.

The company is preparing for a “day-one” semaglutide launch once the patent expires in March 2026. Validation work is underway at its Swiss Parenterals unit, and in-house production is expected to start later this year, according to the provided context.

FY27 outlook: domestic growth and international revenue target

Eris said it remains optimistic about its growth trajectory, with guidance spanning both domestic and international operations. It projects its international business to generate INR 550-600 crore in revenue by FY27. It also expects domestically, branded formulations to grow 12-14%.

The company also stated it has “strong visibility” of FY27 revenue of INR 550-600 crore, alongside EBITDA of INR 180-200 crore in the same outlook section. Investors are likely to parse how these targets align with the company’s segment reporting and how much of the FY27 margin profile depends on insourcing and semaglutide scaling.

Key numbers table

What to watch next

The near-term execution focus is split between two core areas: stabilising insulin supply through manufacturing readiness, and scaling semaglutide through partnerships and internal capability buildout. The Bhopal facility timeline and the extent of insourcing benefits remain central to improving operating leverage. On semaglutide, the pace of adoption, the mix between vials and pens, and the rollout economics under co-marketing will shape margins.

Eris has already flagged a FY27 EBITDA margin anchor of around 37%, with further improvement expected in the second half as it initiates in-house development of semaglutide pens. Separately, the company’s international revenue target of INR 550-600 crore by FY27 sets a measurable milestone. The next set of quarterly updates should provide clearer evidence on whether supply constraints ease and whether early GLP-1 traction sustains beyond the initial launch month.